![Matthew Fearer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Matthew Fearer worked as a Senior Director of Corporate Communications at Acceleron Pharma, Inc. from 2021 to 2022.
He also served as the Director of Communications & Public Affairs at the Whitehead Institute for Biomedical Research.
In 2023, he was the Vice President of Corporate Communications at Viridian Therapeutics, Inc.
Ehemalige bekannte Positionen von Matthew Fearer
| Unternehmen | Position | Ende |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Public Communications Contact | 01.12.2023 |
| ACCELERON PHARMA INC. | Public Communications Contact | 01.04.2022 |
Whitehead Institute for Biomedical Research
 Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Provides research and technology services | Public Communications Contact | 01.10.2016 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
10
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company which develops protein therapeutics for cancer and orphan diseases | Health Technology |
Whitehead Institute for Biomedical Research
Whitehead Institute for Biomedical Research Miscellaneous Commercial ServicesCommercial Services Provides research and technology services | Commercial Services |
Viridian Therapeutics, Inc.
 Viridian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures monoclonal antibody products | Health Technology |
